Literature DB >> 7358773

Experimental investigations on a sequential combination chemotherapy protocol.

H O Klein, H J Toermer, E Christian, C Coerper, K J Lennartz, G Akokan.   

Abstract

This paper deals with experimental investigations concerning the composition of a cytostatic three-drug-protocol in diploid Ehrlich-Ascites-Tumor (EAT) cells in vivo at a far advanced stage of the disease. Hydroxyurea (HU) and vincristine (VCR) were used in very low doses to induce a modification of the growth pattern of tumor cells alike partial synchronization. Adriamycin (ADM) was selected as cytocidal drug during DNA synthesis of the partially synchronized cells. It was found that the sequential combination of HU and VCR (first HU and 12 h thereafter VCR) caused the greatest alteration of growth pattern compared with other combination protocols. A further statistically significant increase of the degree of synchrony was observed after a second VCR administration -- 22 h after HU. By means of this protocol the EAT was subdivided into two proliferating subpopulations, a diploid and tetraploid one. The tetraploid population resulted from surviving cells being not able to perform dytokinesis correctly, so that polynuclear cells and cells with a large single nucleus containing tetraploid DNA values were created. With respect to therapy, the administation of ADM at the time of DNA synthesis of the partially synchronized cells resulted in a statistically significant prolongation of the mean survival time and in 30% of cures of the animals. The dosage of ADM was 2.6 mg/kg, i.e., a nonlethal dose (50% of the LD10). Other combinations, i.e., simultaneous or reversed sequential combinations, did not show any therapeutic improvement compared to single drug therapy of ADM.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7358773     DOI: 10.1007/bf00412898

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment.

Authors:  P G Plagemann; D P Richey; J M Zylka; J Erbe
Journal:  Exp Cell Res       Date:  1974-02       Impact factor: 3.905

2.  Comparison of the effects of several inhibitors of the synthesis of nucleic acids upon the viability and progression through the cell cycle of cultured H. Ep. no. 2 cells.

Authors:  G P Wheeler; B J Bowdon; D J Adamson; M H Vail
Journal:  Cancer Res       Date:  1972-12       Impact factor: 12.701

3.  [Effects of dauno-rubidomycin and adriamycin on enzymes of DNA synthesis in leukocytes in vivo and in culture].

Authors:  K Wilms; W Wilmanns
Journal:  Klin Wochenschr       Date:  1972-09-15

4.  Antineoplastic drug activity in the mitotic cycle--effects of six agents on macromolecular synthesis in synchronous mammalian leukemic cells.

Authors:  H B Bosmann
Journal:  Biochem Pharmacol       Date:  1972-07-15       Impact factor: 5.858

5.  Continuous inhibition of DNA synthesis in mouse ear epidermis using hydroxyurea.

Authors:  R M Singer; S Gelfant
Journal:  Exp Cell Res       Date:  1972-07       Impact factor: 3.905

Review 6.  Cancer chemotherapy.

Authors:  A C Sartorelli; W A Creasey
Journal:  Annu Rev Pharmacol       Date:  1969       Impact factor: 13.820

7.  Interference of daunomycin with metabolic events of the cell cycle in synchronized cultures of rat fibroblasts.

Authors:  R Silvestrini; A Di Marco; T Dasdia
Journal:  Cancer Res       Date:  1970-04       Impact factor: 12.701

8.  The effect of vincristine on mouse jejunal crypt cells of differing cell age: double labelling autoradiographic studies using 3H- and 14C-TdR.

Authors:  W Jellinghaus; B Schultze; W Maurer
Journal:  Cell Tissue Kinet       Date:  1977-03

9.  Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle.

Authors:  W K Sinclair
Journal:  Science       Date:  1965-12-24       Impact factor: 47.728

10.  [Biological activity of adriamycin in vitro].

Authors:  R Silvestrini; C Gambarucci; T Dasdia
Journal:  Tumori       Date:  1970 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.